Galectin Therapeutics
GALT
GALT
98 hedge funds and large institutions have $38.6M invested in Galectin Therapeutics in 2026 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
1% more funds holding
Funds holding: 97 → 98 (+1)
19% less capital invested
Capital invested by funds: $47.9M → $38.6M (-$9.3M)
Holders
98
Holding in Top 10
–
Calls
$5.72M
Puts
$313K
Top Buyers
| 1 | +$1.88M | |
| 2 | +$1.71M | |
| 3 | +$1.37M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$883K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$818K |
Top Sellers
| 1 | -$592K | |
| 2 | -$532K | |
| 3 | -$423K | |
| 4 |
Goldman Sachs
New York
|
-$373K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$343K |
